CCDC125
gene geneOn this page
Also known as KENAE
Summary
CCDC125 (coiled-coil domain containing 125, HGNC:28924) is a protein-coding gene on chromosome 5q13.2, encoding Coiled-coil domain-containing protein 125 (Q86Z20). May be involved in the regulation of cell migration.
Enables identical protein binding activity. Involved in activation of GTPase activity; negative regulation of Rho protein signal transduction; and negative regulation of cell motility. Located in cytoplasm.
Source: NCBI Gene 202243 — RefSeq curated summary.
At a glance
- GWAS associations: 13
- Clinical variants (ClinVar): 88 total — 1 likely-pathogenic
- MANE Select transcript:
NM_176816
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:28924 |
| Approved symbol | CCDC125 |
| Name | coiled-coil domain containing 125 |
| Location | 5q13.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | KENAE |
| Ensembl gene | ENSG00000183323 |
| Ensembl biotype | protein_coding |
| OMIM | 613781 |
| Entrez | 202243 |
Gene structure
Transcript identifiers
Ensembl transcripts: 10 — 7 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron
ENST00000383374, ENST00000396496, ENST00000396499, ENST00000460090, ENST00000511257, ENST00000512045, ENST00000513172, ENST00000877999, ENST00000878000, ENST00000878001
RefSeq mRNA: 3 — MANE Select: NM_176816
NM_001297696, NM_001297697, NM_176816
CCDS: CCDS4000, CCDS75255
Canonical transcript exons
ENST00000396496 — 12 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001293712 | 69292188 | 69292362 |
| ENSE00001496533 | 69332649 | 69332801 |
| ENSE00001648227 | 69303847 | 69303929 |
| ENSE00001658612 | 69307951 | 69308028 |
| ENSE00001746787 | 69306817 | 69306902 |
| ENSE00002021812 | 69280175 | 69283034 |
| ENSE00003533595 | 69294793 | 69294900 |
| ENSE00003572217 | 69285337 | 69285467 |
| ENSE00003574552 | 69313985 | 69314046 |
| ENSE00003579767 | 69300012 | 69300127 |
| ENSE00003598255 | 69320237 | 69320580 |
| ENSE00003625936 | 69311118 | 69311204 |
Expression profiles
Bgee: expression breadth ubiquitous, 180 present calls, max score 87.78.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.0120 / max 54.2742, expressed in 1241 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 62015 | 3.0120 | 1241 |
Top tissues by expression
253 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| bone marrow cell | CL:0002092 | 87.78 | gold quality |
| oviduct epithelium | UBERON:0004804 | 83.36 | gold quality |
| right uterine tube | UBERON:0001302 | 83.30 | gold quality |
| right lobe of liver | UBERON:0001114 | 82.52 | gold quality |
| bone marrow | UBERON:0002371 | 81.14 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 80.88 | gold quality |
| bronchial epithelial cell | CL:0002328 | 80.72 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 80.58 | gold quality |
| monocyte | CL:0000576 | 80.50 | gold quality |
| rectum | UBERON:0001052 | 80.36 | gold quality |
| leukocyte | CL:0000738 | 80.20 | gold quality |
| buccal mucosa cell | CL:0002336 | 80.15 | silver quality |
| calcaneal tendon | UBERON:0003701 | 79.45 | gold quality |
| bronchus | UBERON:0002185 | 79.08 | gold quality |
| islet of Langerhans | UBERON:0000006 | 78.62 | gold quality |
| tendon | UBERON:0000043 | 78.19 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 77.58 | gold quality |
| liver | UBERON:0002107 | 77.52 | gold quality |
| blood | UBERON:0000178 | 77.26 | gold quality |
| stromal cell of endometrium | CL:0002255 | 77.15 | gold quality |
| tendon of biceps brachii | UBERON:0008188 | 77.12 | gold quality |
| gall bladder | UBERON:0002110 | 77.09 | gold quality |
| minor salivary gland | UBERON:0001830 | 76.63 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 76.20 | gold quality |
| body of pancreas | UBERON:0001150 | 76.05 | gold quality |
| fallopian tube | UBERON:0003889 | 75.92 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 75.81 | gold quality |
| prostate gland | UBERON:0002367 | 75.74 | gold quality |
| pancreas | UBERON:0001264 | 75.72 | gold quality |
| right adrenal gland | UBERON:0001233 | 75.18 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 5.69 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
60 targeting CCDC125, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3646 | 100.00 | 73.56 | 5283 |
| HSA-MIR-5692A | 100.00 | 74.40 | 6850 |
| HSA-MIR-4282 | 99.99 | 75.36 | 6408 |
| HSA-MIR-371B-5P | 99.99 | 75.34 | 4759 |
| HSA-MIR-373-5P | 99.98 | 75.36 | 4753 |
| HSA-MIR-616-5P | 99.98 | 75.58 | 4775 |
| HSA-MIR-548AJ-3P | 99.96 | 73.38 | 5345 |
| HSA-MIR-548X-3P | 99.96 | 73.38 | 5345 |
| HSA-MIR-6778-3P | 99.96 | 67.29 | 2693 |
| HSA-MIR-548J-3P | 99.94 | 72.61 | 4881 |
| HSA-MIR-9983-3P | 99.94 | 71.48 | 3631 |
| HSA-MIR-548AE-3P | 99.93 | 72.66 | 4867 |
| HSA-MIR-548AH-3P | 99.93 | 72.54 | 4872 |
| HSA-MIR-548AM-3P | 99.93 | 72.54 | 4872 |
| HSA-MIR-548AQ-3P | 99.93 | 72.66 | 4867 |
| HSA-MIR-8063 | 99.91 | 69.76 | 3146 |
| HSA-MIR-380-3P | 99.89 | 70.18 | 1978 |
| HSA-MIR-153-5P | 99.89 | 73.86 | 6317 |
| HSA-MIR-4496 | 99.88 | 68.89 | 2236 |
| HSA-MIR-129-5P | 99.88 | 70.26 | 3273 |
| HSA-MIR-182-5P | 99.87 | 74.03 | 2589 |
| HSA-MIR-579-3P | 99.86 | 71.66 | 3628 |
| HSA-MIR-383-3P | 99.85 | 65.84 | 1359 |
| HSA-MIR-664B-3P | 99.84 | 71.65 | 3590 |
| HSA-MIR-577 | 99.78 | 69.13 | 2479 |
| HSA-MIR-6885-3P | 99.75 | 70.36 | 3187 |
| HSA-MIR-4470 | 99.66 | 69.35 | 1767 |
| HSA-MIR-1827 | 99.63 | 68.57 | 3265 |
| HSA-MIR-24-3P | 99.59 | 69.97 | 1934 |
| HSA-MIR-106A-3P | 99.53 | 67.58 | 995 |
Literature-anchored findings (GeneRIF, showing 1)
- These results suggest that the novel gene, Kenae/CCDC125, acts as a regulator of cell motility through RhoA, Rac1 and cdc42. (PMID:19787194)
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Ccdc125 | ENSMUSG00000048924 |
| rattus_norvegicus | Ccdc125 | ENSRNOG00000027410 |
Protein
Protein identifiers
Coiled-coil domain-containing protein 125 — Q86Z20 (reviewed: Q86Z20)
Alternative names: Protein kenae
All UniProt accessions (2): Q86Z20, F8W912
UniProt curated annotations — full annotation on UniProt →
Function. May be involved in the regulation of cell migration.
Subcellular location. Cytoplasm.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q86Z20-1 | 1, Kenae-1 | yes |
| Q86Z20-2 | 2, Kenae-2 |
RefSeq proteins (3): NP_001284625, NP_001284626, NP_789786* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR034608 | CCDC125 | Family |
UniProt features (10 total): compositionally biased region 3, coiled-coil region 2, chain 1, region of interest 1, modified residue 1, splice variant 1, sequence variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q86Z20-F1 | 67.24 | 0.32 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (1): 504
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 100 (showing top):
GOBP_ACTIVATION_OF_GTPASE_ACTIVITY, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, GOBP_REGULATION_OF_GTPASE_ACTIVITY, GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, TAL1ALPHAE47_01, GOBP_NEGATIVE_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY, GOBP_REGULATION_OF_HYDROLASE_ACTIVITY, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_NEGATIVE_REGULATION_OF_RHO_PROTEIN_SIGNAL_TRANSDUCTION, GOBP_REGULATION_OF_RHO_PROTEIN_SIGNAL_TRANSDUCTION, BROWN_MYELOID_CELL_DEVELOPMENT_UP, GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, ZHAN_MULTIPLE_MYELOMA_CD1_DN
GO Biological Process (4): negative regulation of Rho protein signal transduction (GO:0035024), activation of GTPase activity (GO:0090630), negative regulation of cell motility (GO:2000146), regulation of cell motility (GO:2000145)
GO Molecular Function (2): identical protein binding (GO:0042802), protein binding (GO:0005515)
GO Cellular Component (1): cytoplasm (GO:0005737)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cell motility | 2 |
| Rho protein signal transduction | 1 |
| regulation of Rho protein signal transduction | 1 |
| negative regulation of small GTPase mediated signal transduction | 1 |
| positive regulation of GTPase activity | 1 |
| negative regulation of locomotion | 1 |
| negative regulation of cellular process | 1 |
| regulation of cell motility | 1 |
| regulation of locomotion | 1 |
| regulation of cellular process | 1 |
| protein binding | 1 |
| binding | 1 |
| intracellular anatomical structure | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
324 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| CCDC125 | CCDC74B | Q96LY2 | 624 |
| CCDC125 | CFAP184 | Q2M329 | 614 |
| CCDC125 | CFAP263 | Q9H0I3 | 540 |
| CCDC125 | CCDC70 | Q6NSX1 | 537 |
| CCDC125 | CCDC92 | Q53HC0 | 526 |
| CCDC125 | C9orf153 | Q5TBE3 | 514 |
| CCDC125 | BICDL1 | Q6ZP65 | 485 |
| CCDC125 | RASL11B | Q9BPW5 | 454 |
| CCDC125 | TACC1 | O75410 | 443 |
| CCDC125 | CCDC169 | A6NNP5 | 435 |
| CCDC125 | CCDC190 | Q86UF4 | 431 |
| CCDC125 | POLR2B | P30876 | 421 |
| CCDC125 | TLCD2 | A6NGC4 | 415 |
| CCDC125 | CCDC42 | Q96M95 | 412 |
| CCDC125 | TXNDC15 | Q96J42 | 408 |
IntAct
198 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| CCDC125 | ZNF343 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CCDC125 | CDC23 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CCDC125 | OTOS | psi-mi:“MI:0915”(physical association) | 0.560 |
| ATOSB | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CCDC125 | FAM161B | psi-mi:“MI:0915”(physical association) | 0.560 |
| RAB2A | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZNF165 | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
| NEBL | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CCDC125 | ZNF337 | psi-mi:“MI:0915”(physical association) | 0.560 |
| EIF3D | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TRIM14 | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CCDC125 | ZNF837 | psi-mi:“MI:0915”(physical association) | 0.560 |
| C21orf58 | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CCDC125 | KAT5 | psi-mi:“MI:0915”(physical association) | 0.560 |
| GEM | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TSGA10IP | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZNF792 | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CCDC125 | SPMIP2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CCDC125 | ZNF587 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CCDC125 | ZNF764 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TEAD4 | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CCDC125 | AIRIM | psi-mi:“MI:0915”(physical association) | 0.560 |
| CCDC125 | CEP95 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZNF883 | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CCDC125 | ZNF564 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CDK18 | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MYH1 | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZFP1 | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
| NSMF | CCDC125 | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (68): CCDC125 (Two-hybrid), CCDC125 (Two-hybrid), CCDC125 (Two-hybrid), CCDC125 (Two-hybrid), CCDC125 (Two-hybrid), CCDC125 (Two-hybrid), CCDC125 (Two-hybrid), CCDC125 (Two-hybrid), CCDC125 (Two-hybrid), CCDC125 (Two-hybrid), CCDC125 (Two-hybrid), CCDC125 (Two-hybrid), CCDC125 (Two-hybrid), CCDC125 (Two-hybrid), CCDC125 (Two-hybrid)
ESM2 similar proteins: A0A1W2P884, A2AM05, A2AUM9, A2BGP7, E1U8D0, O94964, P60853, Q05D60, Q0KK56, Q2M243, Q32LC2, Q3UPP8, Q3V036, Q5PQQ9, Q5PQS2, Q5R9L2, Q5SZL2, Q5U3Z6, Q5U465, Q5U4W1, Q5XJA2, Q6AXZ4, Q6AYB8, Q6DIS8, Q6IPM2, Q6NRK1, Q6NRX3, Q6P2H3, Q6P402, Q6PCQ0, Q70YC5, Q7M6Y5, Q86YF9, Q86Z20, Q8BG89, Q8BMD2, Q8BMK0, Q8BVC4, Q8CFC9, Q8CGZ2
Diamond homologs: A2BGP7, Q5U465, Q86Z20
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 66 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Activation of BAD and translocation to mitochondria | 5 | 100.2× | 7e-08 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 5 | 88.4× | 9e-08 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 5 | 88.4× | 9e-08 |
| Activation of BH3-only proteins | 5 | 65.3× | 3e-07 |
| RHO GTPases activate PKNs | 5 | 41.7× | 3e-06 |
| Intrinsic Pathway for Apoptosis | 5 | 38.5× | 4e-06 |
| SARS-CoV-1-host interactions | 5 | 23.1× | 4e-05 |
| Apoptosis | 5 | 22.1× | 4e-05 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
88 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 1 |
| Uncertain significance | 64 |
| Likely benign | 4 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (1)
| Variant ID | HGVS | Classification |
|---|---|---|
| 563075 | GRCh37/hg19 5q12.3-13.2(chr5:65315606-68755816)x1 | Likely pathogenic |
SpliceAI
3018 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 5:69282889:CG:C | donor_gain | 1.0000 |
| 5:69283030:TTAAG:T | acceptor_gain | 1.0000 |
| 5:69283031:TAAG:T | acceptor_gain | 1.0000 |
| 5:69283032:AAG:A | acceptor_gain | 1.0000 |
| 5:69283033:AG:A | acceptor_gain | 1.0000 |
| 5:69283034:GC:G | acceptor_loss | 1.0000 |
| 5:69283035:C:A | acceptor_loss | 1.0000 |
| 5:69283035:C:CC | acceptor_gain | 1.0000 |
| 5:69283036:T:G | acceptor_loss | 1.0000 |
| 5:69283038:CA:C | acceptor_gain | 1.0000 |
| 5:69283039:A:AC | acceptor_gain | 1.0000 |
| 5:69283039:A:C | acceptor_gain | 1.0000 |
| 5:69283044:C:CT | acceptor_gain | 1.0000 |
| 5:69283045:A:T | acceptor_gain | 1.0000 |
| 5:69300123:CAAAA:C | acceptor_gain | 1.0000 |
| 5:69300128:C:CC | acceptor_gain | 1.0000 |
| 5:69313878:C:CT | acceptor_gain | 1.0000 |
| 5:69320577:CTGT:C | acceptor_gain | 1.0000 |
| 5:69320581:C:CC | acceptor_gain | 1.0000 |
| 5:69282888:A:AC | donor_gain | 0.9900 |
| 5:69282888:ACG:A | donor_gain | 0.9900 |
| 5:69282889:C:CC | donor_gain | 0.9900 |
| 5:69282889:CGC:C | donor_gain | 0.9900 |
| 5:69283042:C:CT | acceptor_gain | 0.9900 |
| 5:69292369:T:C | acceptor_gain | 0.9900 |
| 5:69292369:T:TC | acceptor_gain | 0.9900 |
| 5:69294794:T:TA | donor_gain | 0.9900 |
| 5:69300008:CTA:C | donor_loss | 0.9900 |
| 5:69300010:A:AG | donor_loss | 0.9900 |
| 5:69300011:CCTC:C | donor_loss | 0.9900 |
AlphaMissense
3430 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 5:69292309:G:C | F326L | 0.990 |
| 5:69292309:G:T | F326L | 0.990 |
| 5:69292311:A:G | F326L | 0.990 |
| 5:69282990:G:C | S425R | 0.989 |
| 5:69282990:G:T | S425R | 0.989 |
| 5:69282992:T:G | S425R | 0.989 |
| 5:69292297:A:C | F330L | 0.986 |
| 5:69292297:A:T | F330L | 0.986 |
| 5:69292299:A:G | F330L | 0.986 |
| 5:69292332:C:G | A319P | 0.985 |
| 5:69283016:C:G | A417P | 0.983 |
| 5:69292314:C:G | A325P | 0.983 |
| 5:69294852:A:G | C289R | 0.982 |
| 5:69282999:T:A | R422S | 0.981 |
| 5:69282999:T:G | R422S | 0.981 |
| 5:69294850:A:C | C289W | 0.980 |
| 5:69311141:C:G | A144P | 0.980 |
| 5:69311179:A:G | L131P | 0.980 |
| 5:69282980:C:G | A429P | 0.979 |
| 5:69292320:C:G | A323P | 0.979 |
| 5:69282982:A:G | L428P | 0.978 |
| 5:69294882:A:G | C279R | 0.978 |
| 5:69283003:T:G | Q421P | 0.977 |
| 5:69283007:G:C | H420D | 0.975 |
| 5:69306884:A:G | W184R | 0.975 |
| 5:69306884:A:T | W184R | 0.975 |
| 5:69311128:A:G | L148P | 0.975 |
| 5:69311158:A:G | L138P | 0.975 |
| 5:69294880:G:C | C279W | 0.974 |
| 5:69292306:T:A | R327S | 0.973 |
dbSNP variants (sampled 300 via entrez): RS1000025282 (5:69316765 G>A), RS1000066371 (5:69295015 CA>C,CAA), RS1000093550 (5:69334054 G>A,T), RS1000125340 (5:69317172 C>A,T), RS1000221720 (5:69315282 G>A), RS1000270662 (5:69333086 G>T), RS1000308433 (5:69289080 G>A,C), RS1000327476 (5:69308287 C>G), RS1000327949 (5:69300658 A>G), RS1000537827 (5:69288295 A>G), RS1000611255 (5:69290900 G>C), RS1000657960 (5:69334416 A>G), RS1000663079 (5:69302703 G>A), RS1000822759 (5:69296699 T>C), RS1000836867 (5:69334342 G>T)
Disease associations
OMIM: gene MIM:613781 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
13 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004608_13 | Granulocyte percentage of myeloid white cells | 3.000000e-12 |
| GCST004610_74 | White blood cell count | 3.000000e-12 |
| GCST004613_138 | Sum neutrophil eosinophil counts | 4.000000e-15 |
| GCST004614_155 | Granulocyte count | 2.000000e-15 |
| GCST004620_151 | Sum basophil neutrophil counts | 1.000000e-15 |
| GCST004626_45 | Myeloid white cell count | 9.000000e-14 |
| GCST004629_66 | Neutrophil count | 2.000000e-15 |
| GCST004633_54 | Neutrophil percentage of white cells | 1.000000e-09 |
| GCST90002389_204 | Lymphocyte percentage of white cells | 1.000000e-13 |
| GCST90002394_69 | Monocyte percentage of white cells | 1.000000e-10 |
| GCST90002398_467 | Neutrophil count | 2.000000e-31 |
| GCST90002399_392 | Neutrophil percentage of white cells | 9.000000e-20 |
| GCST90002407_458 | White blood cell count | 9.000000e-22 |
EFO canonical traits (8, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0007997 | granulocyte percentage of myeloid white cells |
| EFO:0004833 | neutrophil count |
| EFO:0004842 | eosinophil count |
| EFO:0007987 | granulocyte count |
| EFO:0005090 | basophil count |
| EFO:0007990 | neutrophil percentage of leukocytes |
| EFO:0007993 | lymphocyte percentage of leukocytes |
| EFO:0007989 | monocyte percentage of leukocytes |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
26 total (human), top 26 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| potassium chromate(VI) | affects cotreatment, decreases expression | 2 |
| Tobacco Smoke Pollution | decreases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| bisphenol A | decreases expression | 1 |
| beta-lapachone | increases expression | 1 |
| aflatoxin B2 | increases methylation | 1 |
| S-(1,2-dichlorovinyl)cysteine | affects response to substance, increases expression | 1 |
| epigallocatechin gallate | affects cotreatment, decreases expression | 1 |
| avobenzone | decreases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| chromium hexavalent ion | decreases expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| ICG 001 | increases expression | 1 |
| 4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid | increases expression | 1 |
| Temozolomide | decreases expression | 1 |
| Acetaminophen | decreases expression | 1 |
| Air Pollutants | increases abundance, increases expression | 1 |
| Lipopolysaccharides | decreases expression, affects response to substance, increases expression | 1 |
| Smoke | increases abundance, increases expression | 1 |
| Urethane | decreases expression | 1 |
| Cyclosporine | decreases expression | 1 |
| Aflatoxin B1 | increases methylation | 1 |
| Copper Sulfate | decreases expression | 1 |
| Lactic Acid | decreases expression | 1 |
| Vitamin K 3 | affects expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.